Preclinical Evaluation of the Effects of Trazpiroben (TAK-906), a Novel, Potent Dopamine D<sub>2</sub>/D<sub>3</sub> Receptor Antagonist for the Management of Gastroparesis
The journal of pharmacology and experimental therapeutics/The Journal of pharmacology and experimental therapeutics